June 15-18, 2015 | Philadelphia, PA

Buzz of BIO

Thanks for Voting! Winners Will Be Announced Soon.

Thanks for voting for your favorite innovative biotech company in the Pipelines of Promise and Technologies of Tomorrow categories. One vote per person, per day will be strictly enforced. See contest rules. The company with the most votes in each category will win one complimentary Convention Access & Partnering pass as well as a free Company Presentation in the BIO Business Forum in front of industry leaders. Winners will be announced on April 30, 2015.

 

Share:

Voting is now closed!

Thank you to the thousands of you that participated in our Buzz of BIO Contest® and most importantly to all of our nominees and finalists! We are so grateful for your work and your commitment to helping others.

Stay tuned for details on the announcement of winners and you can expect to see many of the finalists in June at BIO 2015.

  • Pipelines of Promise
  • Technologies of Tomorrow
Votes
268
Facebook
Twitter
Linkedin

Anavex Life Sciences Corp.

Anavex develops novel drugs for CNS diseases, pain & various types of cancer. Lead candidates ANAVEX 2-73 & ANAVEX PLUS, which combines 2-73 w/ donepezil (Aricept®), are in Phase 2a Alzheimer’s trial. ANAVEX 2-73 has clean Phase 1 profile & preclinical shows it may halt &/or reverse Alzheimer’s.

3 reasons to vote for us:

1. Drugs in adaptive Phase 2a trial have de-risked regulatory pathway & potential to modify Alzheimer’s
2. Anavex has strong team and is fully funded through completion of current Phase 2a Alzheimer’s trial
3. Pipeline of other CNS and cancer therapeutics w/ opportunities for licensing and/or partnering
Votes
234

Arvinas

Arvinas is commercializing a unique technology to specifically degrade cellular proteins. Bifunctional small molecules that simultaneously bind to the target protein and an E3 ubiquitin ligase lead to ubiquitination and subsequent degradation of the protein, greatly increasing “druggable” targets.

3 reasons to vote for us:

1. Completely new paradigm for drug action.
2. Ability to reduce levels of most proteins, including currently "undruggable" targets.
3. Great story of cooperation between academia, the Bioscience business community, VCs and the state.
Votes
291
Facebook
Linkedin

BioAegis Therapeutics, Inc.

BioAegis Therapeutics is a clinical stage company harnessing the body's innate immunity to reduce serious outcomes in diseases driven by inflammation. BioAegis is commercializing biomarker-driven therapy resulting from groundbreaking medical discoveries from Harvard Med School.

3 reasons to vote for us:

1. No other molecules that modulate inflammation AND boost immune function
2. Cusp of changing way that inflammation and infection are treated
3. Broad medical impact to save lives and reduce costs!
Votes
375

ImaginAb, Inc.

ImaginAb harnesses the specificity of monoclonal antibodies to engineer small, highly targeted proteins for imaging important molecular targets in oncology and immunology with positron emission tomography. Our concept is "If we can see the cancer, we can treat it more effectively..."

3 reasons to vote for us:

1. ImaginAb's platform technology will enable cancer patients to receive therapy tailored for them.
2. ImaginAb's lead candidate in prostate cancer will help clinicians to manage patient therapy.
3. ImaginAb's has a rich pipeline in imaging targets for immuno-oncology.
Votes
171
Twitter
Linkedin

Immunexpress

Immunexpress is a molecular diagnostic company committed to improving outcomes for patients with, and, at risk of, sepsis. Their SeptiCyte technology measures a patient’s specific immune response to infection to aid in the detection and clinical assessment of sepsis in critical care patients.

3 reasons to vote for us:

1. Novel approach to sepsis diagnostics looks at host response instead of presence of pathogen
2. SeptiCyte aids in diagnosing sepsis cases with high sensitivity in <4 hours
3. Pipeline aims to provide a result in only one hour at the bedside of patient in the hospital
Votes
625
Twitter
Linkedin

KinderPharm LLC

KinderPharm is a clinical stage, specialty pharmaceutical company with expert resources focused exclusively on pediatric drug development. Our “Single-Point-of-Accountability” model for formulation development, pediatric PK/PD analysis, pediatric dose prediction, clinical trials and regulatory submission provides an efficient and effective one-stop shop for our clients.

3 reasons to vote for us:

1. KinderPharm is the only company in the USA to focus solely on Pediatric Drug Development.
2. KinderPharm provides educational lunch and learn workshops to help educate on pediatric regulations.
3. KinderPharm is focused on innovative dosing models to support efficient pediatric clinical trials.
Votes
111

MenoGeniX

A clinical stage biotech - and recently completed a Phase 1b trial is developing MNGX-100 a G-CSF based therapy as a non-hormonal and non-SSRI therapy without the associated risks to treat hot-flashes and other menopausal symptoms. There are over 70 million women with symptoms who seek therapy.

3 reasons to vote for us:

1. If approved MNGX-100 could offer an alternative to current therapies without the associated risks
2. Repurposing a drug accelerates the path to approval & cuts down on development costs
3. If approved, MNGX-100 could provide relief for naturally occurring & surgically induced menopause
Votes
193
Facebook
Twitter

Metaclipse Therapeutics

Metaclipse is developing patient-specific cancer therapies designed to activate the immune system to mount a robust attack against metastatic cells. These products consist of micron-size ‘vesicles’ manufactured from tumor tissue and modified with proprietary immunostimulatory proteins.

3 reasons to vote for us:

1. Unique personalized cancer immunotherapy to treat or control metastatic disease
2. Platform technology applicable to various cancer types with no need to identify genetic variation
3. Rapid, simple, cost-effective process adaptable to on-site hospital settings
Votes
244
Facebook
Twitter
Linkedin
Video

NeoStem

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based personalized medicine therapeutics that prevent, treat or cure disease.

3 reasons to vote for us:

1. Phase 3 melanoma product candidate with Fast Track, SPA, and Orphan Drug designations
2. Diversified, balanced pipeline based on autologous cellular therapies from 3 platform technologies
3. Unique expertise in manufacturing and development of cell therapies (served over 100 clients)
Votes
978
Video

Novavax

We are a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious disease. Our recombinant nanoparticles and Matrix-M adjuvant technology are the basis for ground-breaking innovation that improves global health through safe and effective vaccines.

3 reasons to vote for us:

1. Breakthrough clinical data on our RSV F protein vaccine & initiation of 3 new RSV clinical trials
2. Rapidly developed Ebola vaccine with 100% protection in non-human primates; ongoing clinical trial
3. Revenue growth of 47% to $30 million, employee growth of 55% to 283 & added new facility
Votes
84

Ohmx Corporation

Ohmx is developing a comprehensive diagnostic platform for use at the Point-of-Care (protein, small molecule and DNA compatible). Our platform uses proprietary bioelectronic methods to detect and quantify targets in low-volume samples and provides rapid results with accuracy similar to central labs.

3 reasons to vote for us:

1. Innovative detection allows a single POC platform to measure proteins, small molecules and DNA
2. POC technology can provide reproducibility, accuracy and precision similar to central lab tests
3. Ohmx can bring critical tests & ultrasensitive detection (eg: 1pg/ml for cTnI) to the patient’s side
Votes
86
Facebook
Twitter
Linkedin
Video

Onciomed, Inc.

Welcome. At Onciomed, we are committed to address the worldwide problem of obesity through our breakthrough medical innovations. We are a clinical stage medical device company developing a long term, minimally invasive technology, the Gastric Vest System™ (GVS) to treat obesity and diabetes. Our technology not only enables large medical device and life science corporations to enter the obesity space, but also allows them to penetrate and dominate the $160 billion obesity and diabetes market with our disruptive technology.

3 reasons to vote for us:

1. Onciomed has a next generation minimally invasive technology
2. Onciomed's GVS system meets the large unmet need from 30 Million patients worldwide
3. Onciomed is tomorrow's technology targeting $139.5 Billion annually
Votes
129
Twitter
Linkedin

Qrono, Inc.

Qrono is developing a broad pipeline of long-acting (LA) medicines to deliver drugs over weeks or months. Our computational drug delivery technology provides unprecedented ability to rapidly reformulate approved drugs and NCEs to create LA versions with improved therapeutic and economic benefits.

3 reasons to vote for us:

1. Computational drug delivery collapses the time and cost to design LA medicines while reducing risk.
2. Our in vivo predictions significantly reduce clinical trial and regulatory risk for LA medicines.
3. LA in vitro in vivo correlations (IVIVCs) could revolutionize the generic approval process.
Votes
553
Facebook
Twitter
Linkedin
Video

Rebiotix, Inc.

Rebiotix is a clinical-stage biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.

3 reasons to vote for us:

1. 87% Efficacy in Phase 2 Clinical Trials for Recurrent Clostridium Difficile
2. Fast track orphan status and near term revenue potential
3. Oral formulation and additional therapeutic indications in development
Votes
150
Video

T3D Therapeutics, Inc.

T3D Therapeutics is developing a transformational new drug therapy, T3D-959, for Alzheimer’s disease (AD). This multi-faceted drug which, has successfully completed Phase 1 trials, has the potential to treat multiple pathologies (defects) of AD and slow, stop or reverse the course of disease.

3 reasons to vote for us:

1. Avant-garde approach that runs outside of the mainstream plaque or tau singular focus approaches
2. Compelling pre-clinical proof of concept demonstrating multi-faceted attributes of T3D-959
3. NIA/NIH support and validation, $1.8M Phase 2 SBIR and Banner Alzheimer's Institute collaboration
Votes
1102

Vascular BioSciences (VBS)

VBS is developing our CARSKNKDC (CAR) peptide to enhance the efficacy of co-administered drugs for fatal diseases. CAR has shown success in improving sepsis mortality, in triple-negative breast cancer, ameliorating cachexia, and in enabling pulmonary specific vasodilation in pulmonary hypertension.

3 reasons to vote for us:

1. Novel disease homing cell penetrating peptide
2. Elegant means to achieve targeted drug delivery without conjugation
3. Effective preclinical treatment to improve sepsis mortality
Votes
204
Twitter

4P Therapeutics

We are a 4 year old company with world class science and expertise in the area of transdermal drug delivery including proteins, peptides carbohydrates and other small molecules. We are drug centric in our approach utilizing different proprietary transdermal technologies to succeed in development.

3 reasons to vote for us:

1. Profitable BioTech (transdermal drug delivery) in first full year.
2. Transdermal Technology Innovation includes developing 10 proprietary novel product opportunities.
3. Partnerships established with large and small pharmaceutical companies.
Votes
133
Facebook
Twitter
Linkedin

Acumen Analytics

Acumen Analytics, based in Philadelphia, PA, is a WBE certified information management and analytics consulting firm focused on helping clients leverage their data, technology and organizational assets to create strategies and deliver solutions that drive business outcomes

3 reasons to vote for us:

1. Data driven,optimized,predictive,RBM solution which integrats into existing Clinical solution set
2. HIPPA compliant, SAAS or on-premise application including, RACT, Portfolio, integration and alerts
3. record of global fully compliant Analytics solutions for cost savings & improved safety & trial mgt
Votes
51
Facebook
Twitter
Linkedin
Video

Aventyn, Inc.

Aventyn is an award winning digital health company delivering innovative, secure core to cloud connected clinical information solutions and services to lower health care delivery costs, improve quality and increase patient safety. Vitalbeat, is an easy to use remote chronic disease mgmt system for use by patients and clinicians at home and bedside.

3 reasons to vote for us:

1. Clinical evidence based Vitalbeat remote chronic disease mgmt study outcomes validated by the AHA
2. Vitalbeat remote patient monitoring solution enables patient engagement, adherence and compliance
3. Digital health platform helps lower costs, reduce hosp. readmission with population health analytics
Votes
463
Facebook
Twitter
Linkedin

Boston Mountain Biotech

BMB focuses on purification problems in the pharma industry. We have developed the patented Lotus cell lines that produce less contaminant, thus shortening new product design time. A purer starting point results in high purity protein therapeutics, increased manufacturing, and lower costs.

3 reasons to vote for us:

1. Innovative new startup led by female scientists
2. Changing how the world manufactures proteins
3. Helping bring lower cost drugs to the patients who need them
Votes
249
Video

BRTI Life Sciences

BRTI Life Sciences offers chemically defined, tissue-like, and injectable 3D matrix technologies free of crosslinking agents for tissue engineering and disease modeling applications. Biocompatible matrices create an ideal microenvironment for cancer and stem cells for study in vitro or in vivo.

3 reasons to vote for us:

1. Cell-Mate3D allows research of cellular mechanisms in a biologically relevant microenvironment.
2. Enables complex adipogenic, chondrogenic, osteogenic, and neurogenic development from stem cells.
3. Supports pancreatic islet health, including c-peptide secretion and insulin production in vitro.
Votes
193
Twitter
Video

Click Therapeutics

Engineers, validates, and commercializes Digital Therapeutics™ applications that integrates evidence-based cognitive-behavioral science with powerful data analytics to help individuals manage diseases and health conditions. Interventions can be used independently or with biomedical treatments.

3 reasons to vote for us:

1. Leading innovator/pioneer in Digital Therapeutics™ space
2. Data-driven, science-based, R&D intensive digital therapeutics applicable in many indications
3. Adaptable, personalized digital medicine improve treatment adherence & augment effectiveness
Votes
182
Facebook
Linkedin
Video

Cocoon Biotech

Cocoon Biotech is bringing the freedom of living a healthy productive life to patients worldwide initially through treatments for osteoarthritis using natural silk microspheres as local delivery of biologics. Cocoon has completed seed financing and is demonstrating in vivo safety and efficacy.

3 reasons to vote for us:

1. Service to others: Cocoon is tackling the largest unmet needs: over 175 million with osteoarthritis.
2. Innovation: Cocoon is harnessing the natural lubricating and drug delivery properties of silk.
3. Fiercely efficient: Achieving pre-clincial safety and efficacy with minimal funds and great team.
Votes
143
Facebook
Twitter
Linkedin

EpiVax, Inc.

EpiVax is a global company based in RI that develops novel immunotherapeutics while providing biologics and vaccine design tools to biotech firms. EpiVax focuses in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development.

3 reasons to vote for us:

1. Pioneers the uses of computational immunology for improving biologics and vaccines.
2. Thought Leader in the field of immunogenicity risk assessment and de-risking.
3. "Fearless science" is the company's motto: Not afraid to challenge existing paradigms.
Votes
149
Twitter
Linkedin

Gentox

GenToX is a pharmacogenomics testing company that gives detailed insight into a patient's DNA so doctors can improve their lives. Testing involves a cheek swab for DNA and then the provider is given a detailed patient report to guide treatment in areas such as cardiology and psychiatric care.

3 reasons to vote for us:

1. Local company has experienced rapid growth in a short amount of time.
2. Pharmacogenomic testing is an innovative testing service to offer because of its precision focus.
3. Its focus on the patient is unparalleled to any type of medical care. Treatment is DNA-based.
Votes
738
Twitter
Linkedin

GigaGen, Inc.

GigaGen captures the genetic make-up of the entire human immune repertoire to identify and produce naturally occurring antibodies. We are using our technology to make the first recombinant version of IVIG with a higher potency, better safety, and more reliable supply than the blood derived product.

3 reasons to vote for us:

1. Revolutionary Technology - Microfluidic based platform that processes 1M cells per hour
2. Great Team - David Johnson: Founder of Natera; Carter Keller: Genentech, Achaogen, Exelixis
3. Great Market - Natural IVIG is a $7B blood derived therapy that needs a recombinant option
Votes
297
Facebook
Twitter
Linkedin
Video

HiveBio Community Lab

HiveBio is an open-source biosciences laboratory with a focus on molecular biology and neuroscience. Members pay a fee for access to the lab space, equipment, and educational resources provided by the lab.

3 reasons to vote for us:

1. Inclusivity equals innovation. We do not exclude members based on education, background, or income.
2. Thriving interdisciplinary collaboration produces more effective results than traditional labs.
3. Hands-on research approach drives finding real-world solutions that can be used all over the world.
Votes
97
Twitter
Linkedin

Impel NeuroPharma

Drug delivery company focused on advancing the treatment of CNS diseases by enabling the development of promising therapeutics that have been hindered due to an inability to cross the blood brain barrier. Our nose-to-brain delivery technology offers an opportunity to bypass the blood brain barrier

3 reasons to vote for us:

1. We enable others: There is now hope for the 98% of drug candidates that do not cross the BBB.
2. We collaborate: Our progress is dependent on strategic partnerships with pharma and biotech.
3. We innovate: Continually pushing the boundaries of design to make POD accessible and effective
Votes
69
Facebook
Twitter
Linkedin
Video

IPS-Integrated Project Services, Inc.

IPS is a global provider of technical consulting, design, engineering, construction, project controls, commissioning and qualification services for technically complex and compliant Development and Manufacturing facilities worldwide. Our focus is on getting your project on-line in time and in use.

3 reasons to vote for us:

1. Runs open industry forums with biotech owners to discuss and develop biotech facility of the future
2. IPS is an expert at the application of technology to meet a specific business case.
3. IPS gets clients in business, no matter how small or large the biotech job or challenge.
Votes
243
Video

Nanotechnology Characterization Lab

The Nanotechnology Characterization Lab (NCL) accelerates development of promising nanomedicines by providing “pharmaceutical mentorship” and free non-clinical testing to developers. NCL has tested > 300 nanomedicines, helping several enter and progress through clinical trials.

3 reasons to vote for us:

1. NCL is a public-private partnership, and a collaboration between NIH, FDA, and NIST
2. Beyond testing, NCL develops novel nanomedicine formulations to achieve specific outcomes
3. NCL’s pipeline of in-house formulations include novel combinations of polymers, lipids, and prodrugs
Votes
210

NanoViricides, Inc.

The Company has developed a novel nanotechnology-based platform technology that enables it to rapidly create drugs to destroy viruses and accomplish this in the space of weeks rather than years

3 reasons to vote for us:

1. Novel technology
2. Ability to manufacture novel drugs in commercial quantities
3. Ability to respond to the threat of a novel virus in a short period of time
Votes
277
Facebook
Twitter
Linkedin
Video

Proove Biosciences

Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications.

3 reasons to vote for us:

1. Improving patient lives
2. Providing physicians with information to design better treatment plans to their patients
3. Saving the healthcare industry time and money
Votes
893
Twitter
Linkedin

ProTransit Nanotherapy

Nanotherapy company delivers antioxidant enzymes for treatment of skin photoaging. Enzymes are encapsulated and thereby stabilized for transdermal delivery and slow release of the active enzymes deep in the skin. We replace what the skin loses upon sun exposure & age for next generation skincare.

3 reasons to vote for us:

1. Unique and patented approach to delivery of powerful antioxidants
2. Feasibility shown and now on the verge of final product development/scale-up
3. Much broader applications possible in other diseases where free radicals are involved.
Votes
217

Siamab Therapeutics

Siamab is an entrepreneurial pharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform technology that enables the rapid discovery and development of therapeutic antibodies that bind to a novel class of carbohydrate antigens present on cancer cells. The company’s lead program is in preclinical studies for the treatment of solid tumors.

3 reasons to vote for us:

1. the potential to create life-changing therapies for patients suffering devastating cancers
2. remarkable progress with modest capital raised from a group of forward-thinking angel investors
3. glycans offer a novel set of immuno-modulatory cancer targets
Votes
697
Facebook
Twitter
Linkedin
Video

Vencore Health Analytics

Vencore provides advanced analytic solutions to solve complex problems. Vencore applies analytic methods and advanced machine learning algorithms to integrate & analyze structured & unstructured healthcare data. This results in predictive analytic solutions to address today’s healthcare challenges.

3 reasons to vote for us:

1. Innovative co. with proprietary analytics to mine clin data & improve rare disease diag & treatment
2. Solutions shorten time to rare disease diagnosis, matching right treatment to patient at right time
3. Trusted partner to pharma and biotech industries, committed to improving patient care
Votes
89

Vivoscript, Inc.

We are developing a disruptive technology platform in regenerative medicine: in vivo (or in situ) cell programming using protein drugs. The platform has two key components: 1. using Gene Regulatory Network theory for rational design of cell reprogramming strategy; 2. protein engineering

3 reasons to vote for us:

1. The technology has wide applications: osteoarthritis, diabetes, stroke, etc.
2. Our objective is to achieve "one-time treatment, lifetime benefit."
3. We have got very exciting data in cartilage damage and repair animal model.
Buzz of BIO Contest Rules
X

Thank You

Thank you for nominating the Buzz of BIO! Spread the word by sharing your nomination on the social networks below.

X

One Last Step...

Thank you for voting for the Buzz of BIO! You will receive an email at the address you submitted your vote. Follow the steps in the email to make your vote count.

X

Your Vote Has Been Verified

Thank you for voting for the Buzz of BIO! Your vote has now been verified. Remember, your vote only counts once a day, so be sure to return each day to vote!

X

Thank You

Thank you for voting for the Buzz of BIO! Unfortunately, your votes only count once a day. Be sure to return tomorrow to vote again!

X

Contest Rules

Buzz of BIO™ - Recognizing the most innovative companies at the 2015 BIO International Convention®

OFFICIAL CONTEST RULES
NO PURCHASE NECESSARY, VOID IN PUERTO RICO AND WHERE PROHIBITED.

Any electronic message sent to or received by a service subscriber of any electronic or wireless carrier may incur a standard messaging charge in accordance with that carrier's Terms and Conditions applicable to such customer's particular plan. Contact your electronic or wireless carrier for messaging charges and plan details.

1) Eligibility: The Buzz of BIO- Recognizing the most innovative companies at the 2015 BIO International Convention® contest (the "Contest") is open to legal residents of the 50 United States and the District of Columbia who are 21 years of age or older at time of entry. Employees, officers, directors (and their immediate families and those living in their same household) of the Biotechnology Industry Organization ("BIO" or "Organizer"), or any Contest Sponsor, are not eligible to participate or win. Void in Puerto Rico and where prohibited. Previous winners of any Buzz of BIOcontest (including the Buzz of BIOcontest at (1) the BIO Investor Forum; (2) the BIO CEO & Investor Conference; and, (3) the BIO International Convention) within the past three years (i.e., three years from registration opening for this Contest) are not eligible to participate in or win the Contest. The Contest is subject to all applicable federal, state and local laws and regulations. The Contest will be construed and evaluated according to U.S. law.

2) How to Enter: Log on to http://www.convention.bio.org/buzzofbio/nominations.aspx , upload a logo and submit an entry (less than 300 characters in length) to describe your project, telling us how your technology, business or idea can impact the biotechnology community. When you're satisfied with what you've written, just submit and you'll be automatically entered in the Contest for a chance to win one of the two Grand Prizes of one Convention Access & Partnering Registration (up to $2,999 in value) and an option to present in the BIO Business Forum Presentations (up to $1,500 in value). Contest nomination is open between 9:00:00 AM Eastern Time (ET) on March 31, 2015 and ends at 5:00:00 PM ET on April 7, 2015, or until 40 qualifying nominations have been received (whichever occurs first).

Entries must be complete to be eligible. Entries become the property of Organizer, and will not be returned. Any form of entry by electronic message into this Contest will be deemed made by the named account holder (for the form of electronic submission) who is assigned at the time of entry to the electronic device so used. Limit of one entry per person, per day for this Contest, regardless of method of entry.

All complete and appropriate entries will be considered for judgment for the Grand Prizes. The Organizer, any Contest Sponsor, any Internet access providers, their respective parents, affiliates, divisions, and agencies and each of the foregoing entities' respective employees, officers, directors, shareholders, and agents (collectively, the "Released Parties") are not responsible for incorrect or inaccurate transfer of entry information, human error, technical malfunctions, lost/delayed data transmissions, omission, interruption, deletion, defect, line failures of any telephone network, computer

equipment, software or any combination thereof, inability to access web site or cell number, damage to a user's computer system (hardware and software) due to participation in this Contest or any other problem or error that may occur. No responsibility is assumed for entrant information that is incomplete or incorrectly entered. All entries become the property of the Organizer.

Any entry information collected from the Contest shall be used only in a manner consistent with the consent given by entrants at the time of entry, with these Official Rules, and with Organizer's Online Privacy Policy which can be found at http://www.bio.org/articles/biotechnology-industry-organization-privacy-policy. Participants who submit inaccurate entry data and/or exceed the entry limits may be excluded from participation at any time during the promotion. Entrants agree to be bound by these rules and consent to use of their names and/or photographs for advertising and/or publicity purposes by Organizer and its designees in any and all media without further consideration, except where prohibited by law.

3) Categories and Voting for the Grand Prizes: The two Contest categories are Pipelines of Promise and Technologies of Tomorrow (collectively the "categories"). Qualifying companies for Pipelines of Promise are companies that have at least started some human trials. Qualifying companies for Technologies of Tomorrow are companies that have not yet begun human trials or will not begin human trials.

The first 40 completed entries received between 9:00:00 AM ET on March 31, 2015 and 5:00:00 PM ET on April 7, 2015 will become contest finalists and thus eligible for one of the two Grand Prizes being given away. The Organizer will place entries into qualifying Categories, Pipelines of Promises and Technologies of Tomorrow. The Organizer is the official timekeeper for this Contest.

Each Contest entrant that becomes a finalist will be displayed on www.convention.bio.org/buzzofbio. Users shall vote for the entries that they feel best meet the criteria set forth below. The entries (i.e., one entry from each Category) that have gained the highest number of votes at the conclusion of the community voting period will be the Grand Prize winners. The community voting period begins at 9:00:00 AM ET on April 14, 2015 and ends at 5:00:00 PM ET on April 21, 2015. Only one vote per unique email address per day will be accepted and recorded.

The following criteria, weighed equally, should be taken into consideration by Users when voting: Innovative Technology, Quality of Presentation and Strength of Ideas.

Submissions can be disqualified if the submission either subjects the submitter, BIO or BIO's members, or the BIO International Convention to legal jeopardy or compromises BIO's or BIO's members' good will and/or reputation, intellectual property or trade secret interests. This includes words or imagery that are sexually charged or suggestive, that depict acts of violence or cruelty, that attack or disparage or present in a false light any individual or group of people, that are otherwise vile, nasty or otherwise uncivil, that makes false performance claims about BIO or BIO members, or the BIO International Convention that use the likeness, words, or other intellectual property of a third party or celebrity (for

example, a movie star, rock star, or company) without appropriate permission to do so. Decisions of the Organizer are final - no substitutions will be available.

4) Grand Prize Notification: Each of the winners of the two Grand Prizes will be notified on or about April 30, 2015, by email, or telephone or regular mail. If contacted by telephone or regular mail, potential winners who entered via electronic message methods will be required to provide phone number and mailing address information (e.g., full name, phone number, street address, city, state, and ZIP) in order to receive any necessary prize documents and/or to receive any prize. Entering an incorrect or incomplete e-mail address in the registration process, or failing to meet the eligibility requirements above, will result in contest disqualification. By accepting any prize, winner grants Organizer the right to use his/her entry, name, likeness and biographical information in any and all media for advertising/promotional purposes. Entrants also agree to the release of their name, address, and e-mail information for posting and winner notification purposes. Otherwise, please review this site's privacy policy for more information on how we use any personal data we collect from you.

The judging and selection of each potential Grand Prize winner will be conducted from among all eligible entries received as outlined in Rule #3 above. The Contest will be conducted by ORGANIZER, and their decisions are final and binding on all matters relating to this Contest. Potential winners are subject to eligibility verification and compliance with these official rules. Each potential Grand Prize winner will be required to sign, have notarized and return to ORGANIZER an affidavit of eligibility/release of liability, and, where legal, publicity release within fourteen (14) days of issuance of notification. Failure to complete and return the documents in the time noted or if prize notification is undeliverable for any reason will result in disqualification and an alternate winner(s) will be selected and notified. Each Grand Prize winner must be 21 years of age or older at time of entry. Acceptance of the prize constitutes permission for the Organizer and its designees to use the winner's name and likeness for advertising and promotional purposes without additional compensation unless prohibited by law. Odds of winning a prize are subject to the total number of eligible entries received.

5) Prizes: Two (2) Grand Prize winners will each receive the two Grand Prizes of (1) one (1) Convention Access & Partnering registration (up to $2,999 in value), and (2) an option to make a company presentation in the BIO Business Forum (up to $1,500 in value). Taxes on prizes are solely the responsibility of the winner. The prize is not redeemable in cash and must be accepted as awarded.

If the winner has already registered for or applied to present at the 2015 BIO International Convention and has paid the required fees, the Organizer will reimburse the winner for the price of one (1) Convention Access & Partnering registration, and for the price they paid for the Business Forum company presentation slot.

If, for any reason, a Grand Prize winner cannot accept one of the grand prizes, neither the Organizer nor any Contest Sponsor shall have any further obligation to the Grand Prize winner. All other expenses relating to acceptance of Grand Prize not explicitly stated herein, including but not limited to travel costs, hotel expenses, taxes, ground transportation, meals, beverages, alcoholic beverages, and gratuities or any other miscellaneous travel expenses are the responsibility of Grand Prize winner. Specifics of the Grand Prize are subject to availability and Organizer's sole discretion. Complete terms and conditions of Grand Prize will be furnished with prize notification. Prize is non-transferable. Any element of the Grand Prize, once awarded to the Grand Prize winner, may not be transferred to any other party; no substitutions or cash awards allowed. All details of prize not specified herein shall be determined solely by Organizer. The registration awarded to a Grand Prize winner will become responsibility of the winner upon possession of same and will not be replaced. The terms and conditions of the registration awarded as a prize will govern in the event that the BIO International Convention is unable to take place as planned, is cancelled or postponed, for any reason whatsoever, including an event of force majeure. Organizer has no responsibility to the winner except to provide the registration, and the registration shall constitute full satisfaction of Organizer's prize obligation to the Grand Prize winner, and no other compensation will be awarded. The Organizer, or any of its officials, and/or any other relevant party reserves the right to remove or to deny entry to the winner who engages in an unprofessional or disruptive manner, or with intent to annoy, abuse, threaten or harass any other person at the BIO International Convention. The Approximate Retail Value (ARV) of each registration is up to $2,999, and the ARV of the Presentation, if required, is up to $1,500. Actual value of prize may vary based on whether the winner exercises the option to present at the BIO Business Forum Presentations. Approximate retail value of all prizes is up to $8,998. Any and all guarantees and warranties for the registrations are subject to the terms and conditions of the BIO International Convention, and each winner agrees to look solely to such terms and conditions for any such warranty or guarantee claim. There is a limit of one prize per household.

6) Limitations of Liability: The Released Parties are not responsible for late, lost, stolen, misdirected, damaged, incomplete, or illegible entries; or entries that are lost due to computer, Internet, or electronic malfunction. Organizer reserves the right to cancel or modify contest and award the prize through an alternate means if fraud or technical failure compromises the integrity of the contest, as determined by Organizer in its sole discretion. Entrants agree that the Released Parties shall not be liable for injury, losses, damages, or costs of any kind resulting from participation in this contest or acceptance of or use or misuse of a prize or parts thereof. By entering, participants agree to be bound by these Official Rules. In the event of a dispute regarding the identity of the person submitting an electronic entry, the entry will be deemed to be submitted by the person in whose name the e-mail account is registered or authorized account holder. "Authorized account holder" is defined as the person assigned to an email address by an Internet access provider, online service provider or other organization responsible for assigning email addresses for the domain associated with the email address in question.

Each participant agrees (i) to abide by the terms of these Official Rules and the decisions of the Organizer which are final and binding on all matters relating to this Contest, and (ii) to release, discharge, indemnify and hold harmless the Released Parties from any and all claims, actions, and/or liability for any injuries, loss or damage of any kind arising from or in connection with participation in and/or for entry into this Contest, any related activities, or acceptance or use of any prize won.

This Contest is not intended to be a source of investment advice or recommendation and the Released Parties shall not have any liability for any damages of any kind whatsoever relating to this Contest.

7) General Conditions: Organizer reserves the right to withdraw or terminate this Contest at any time without prior notice. If for any reason this Contest is not capable of running as planned due to infection by computer virus, bugs, tampering, unauthorized intervention, fraud, technical failures, or any other causes beyond the control of the Organizer which corrupt or affect the administration, security, fairness, integrity or proper conduct of this Contest, the Organizer reserves the right at its sole discretion, to disqualify any individual who tampers with the entry process, and to cancel, terminate, modify or suspend the Contest. Should this Contest be terminated, Organizer reserves the right to select potential winner(s) from among all eligible, non-suspect entries received as of the action requiring such termination. The Released Parties are not responsible for any problems or technical malfunction of any computer system, server, or service providers, computer equipment, software, failure of any entry to be received by Organizer on account of technical problems, human error or any combination thereof, including any injury or damage to participant's or any other person's computer equipment relating to or resulting from participation in this sweepstakes.
CAUTION: ANY ATTEMPT TO DELIBERATELY DAMAGE OR UNDERMINE THE LEGITIMATE OPERATION OF THIS SWEEPSTAKES IS A VIOLATION OF CRIMINAL AND CIVIL LAWS AND SHOULD SUCH AN ATTEMPT BE MADE, THE ORGANIZER RESERVES THE RIGHT TO SEEK DAMAGES OR OTHER REMEDIES FROM ANY SUCH PERSON(S) RESPONSIBLE FOR THE ATTEMPT TO THE FULLEST EXTENT PERMITTED BY LAW.

8) Winners List: For the name of Grand Prize winners, available after April 30, 2015, send a stamped, self-addressed envelope to: Buzz of BIO, c/o Brian Pinkston, Biotechnology Industry Organization, 1201 Maryland Avenue SW Suite 900, Washington DC 20024. Requests received after July 1, 2015, will not be honored. Do not send entries or other correspondence to this address.

9) Organizer: The Organizer of this Contest is the Biotechnology Industry Organization (BIO, 1201 Maryland Avenue SW, Washington, DC 20024. ©2015 Biotechnology Industry Organization. All rights reserved. All BIO® -related names, marks, and logos are trademarks of the Biotechnology Industry Organization. All rights reserved. The Buzz of BIO - Recognizing the most innovative companies at the 2015 BIO International Convention contest is a separate and distinct contest from any other Buzz of BIO contest.


Thank you to our 2015 Sponsors

Double Helix Sponsors

Helix Sponsors

Sponsors